{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:46:14Z","timestamp":1791992774795,"version":"4.4.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n Importance<\/jats:title>\n Right ventricular (RV) dysfunction is common among patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and portends worse prognosis. The effects of vutrisiran on RV function remain incompletely characterized.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the prevalence and prognostic importance of RV dysfunction in ATTR-CM, and to evaluate the effect of vutrisiran on RV function.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This post hoc analysis of the HELIOS-B randomized clinical trial (December 2019 and August 2021) included participants with ATTR-CM who had adequate echocardiographic images. Median (IQR) follow-up was 36 (33-36) months. Data analysis was performed from September to December 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Vutrisiran, 25 mg, subcutaneously every 12 weeks vs placebo.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was a composite of all-cause mortality and recurrent cardiovascular events. RV function was assessed using tricuspid annular systolic myocardial velocity (RV S\u2032), RV fractional area change (RV FAC), RV free wall strain (RVFWS), and RVFWS indexed to pulmonary artery systolic pressure (RVFWS\/PASP). Associations with outcomes and treatment effects were evaluated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 655 participants with ATTR-CM who were randomized, 548 had adequate echocardiographic images. The mean (SD) age was 75 (7) years; 506 patients (92%) were men and 42 (8%) were women. RV dysfunction was more prevalent if defined by abnormal RVFWS (absolute RVFWS \u226420%, 85%) vs RV S\u2032 (\u22649.5cm\/s, 56%) or RV FAC (\u226435%, 31%). Patients in the worst RVFWS quartile (&amp;lt;10.8%, n\u2009=\u2009137) had lower estimated glomerular filtration rate, lower left ventricular ejection fraction, and more advanced National Amyloidosis Centre (NAC) stage. Worse RVFWS and RVFWS\/PASP were significantly associated with greater risk of all-cause mortality and recurrent cardiovascular events, independent of clinical characteristics, NAC stage, and LV global longitudinal strain. In contrast, associations of RV S\u2032 and RV FAC with outcomes were attenuated after multivariable adjustment. At 30 months, vutrisiran stabilized RVFWS (between-group difference: 1.6%, 95% CI, 0.7 to 2.6%) and improved RVFWS\/PASP compared with placebo (between-group difference: +0.08%\/mm Hg; 95% CI, 0.03%\/mm Hg to 0.13%\/mm Hg), with no significant effect on RV FAC (\u22121.6%; 95% CI, \u22123.7% to 0.6%).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n RV dysfunction assessed by RVFWS is highly prevalent in ATTR-CM and independently predicts mortality and recurrent CV events, whereas conventional RV measures may underestimate RV dysfunction and lack independent prognostic value. This study found that, consistent with its beneficial effects on other measures of cardiac structure and function, vutrisiran stabilized RVFWS and improved RVFWS\/PASP at 30 months.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04153149<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.3390","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:30:36Z","timestamp":1787758236000},"page":"961","source":"Crossref","is-referenced-by-count":0,"title":["Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy"],"prefix":"10.1001","volume":"11","author":[{"given":"Karola S.","family":"Jering","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Manafi","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Internal Medicine, University of Pittsburgh Medical Center Harrisburg, Harrisburg, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard E.","family":"Bulwer","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Roshanali","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayana","family":"Prasad","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Jay","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Skali","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"hoi260045r1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review.","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"issue":"15","key":"hoi260045r2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","article-title":"Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy.","volume":"149","author":"Porcari","year":"2024","journal-title":"Circulation"},{"issue":"8","key":"hoi260045r3","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jcmg.2021.01.016","article-title":"Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis.","volume":"14","author":"Huntjens","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"hoi260045r4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ehjci\/jeae242","article-title":"Right ventricular free wall strain predicts transthyretin amyloidosis prognosis as well as biomarker-based staging systems.","volume":"26","author":"Istratoaie","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"5","key":"hoi260045r5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jcmg.2018.02.016","article-title":"Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles.","volume":"12","author":"Knight","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"hoi260045r6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacc.2025.06.022","article-title":"Effects of vutrisiran on cardiac function and outcomes in patients with transthyretin amyloidosis with cardiomyopathy.","volume":"86","author":"Jering","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi260045r7","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1093\/ehjci\/jeac253","article-title":"Ratio between right ventricular strain and systolic pulmonary artery pressure as a surrogate for right ventricular to pulmonary arterial coupling: validation against the gold standard.","volume":"24","author":"Richter","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"hoi260045r8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy.","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi260045r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"10","key":"hoi260045r10","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1038\/s41591-025-03851-z","article-title":"Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial.","volume":"31","author":"Jering","year":"2025","journal-title":"Nat Med"},{"issue":"30","key":"hoi260045r11","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis.","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"11","key":"hoi260045r12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.echo.2025.07.007","article-title":"Clinical applications of strain echocardiography: a clinical consensus statement from the American Society of Echocardiography developed in collaboration with the European Association of Cardiovascular Imaging of the European Society of Cardiology.","volume":"38","author":"Thomas","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"hoi260045r13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"hoi260045r14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"hoi260045r15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.echo.2025.01.006","article-title":"Guidelines for the echocardiographic assessment of the right heart in adults and special considerations in pulmonary hypertension: recommendations from the American Society of Echocardiography.","volume":"38","author":"Mukherjee","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"hoi260045r17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/ehjci\/jeu156","article-title":"Traditional and innovative echocardiographic parameters for the analysis of right ventricular performance in comparison with cardiac magnetic resonance.","volume":"16","author":"Focardi","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"11","key":"hoi260045r18","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/echo.14877","article-title":"Comparison of echocardiographic parameters with cardiac magnetic resonance imaging in the assessment of right ventricular function.","volume":"37","author":"Agasthi","year":"2020","journal-title":"Echocardiography"},{"issue":"1","key":"hoi260045r19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jjcc.2022.02.010","article-title":"Prognostic value of right ventricular global longitudinal strain in transthyretin amyloid cardiomyopathy.","volume":"80","author":"Usuku","year":"2022","journal-title":"J Cardiol"},{"issue":"10","key":"hoi260045r20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.echo.2024.06.006","article-title":"Right ventricular strain improves the echocardiographic diagnosis and risk stratification of transthyretin cardiac amyloidosis among other phenotypes of left ventricular hypertrophy.","volume":"37","author":"Ozbay","year":"2024","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"hoi260045r21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jacc.2023.05.010","article-title":"Right ventricular function and pulmonary coupling in patients with heart failure and preserved ejection fraction.","volume":"82","author":"Inciardi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"hoi260045r22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjcard.2024.03.043","article-title":"Optimal method for assessing right ventricular to pulmonary arterial coupling in older healthy adults: the Multi-Ethnic Study of Atherosclerosis.","volume":"222","author":"Jani","year":"2024","journal-title":"Am J Cardiol"},{"issue":"10","key":"hoi260045r23","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1093\/ehjci\/jeaf216","article-title":"Prognostic value of right ventricular longitudinal strain assessed by multimodal imaging in amyloidosis: systematic review and meta-analysis.","volume":"26","author":"Herrera-Flores","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"hoi260045r24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjcard.2022.02.048","article-title":"Prognostic implications of right ventricular systolic dysfunction in cardiac amyloidosis.","volume":"173","author":"Tjahjadi","year":"2022","journal-title":"Am J Cardiol"},{"issue":"10","key":"hoi260045r25","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/ehjci\/jead145","article-title":"Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis.","volume":"24","author":"Tomasoni","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"hoi260045r26","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.echo.2024.08.013","article-title":"Right ventricular to pulmonary artery coupling and prognosis in transthyretin cardiac amyloidosis.","volume":"37","author":"Meucci","year":"2024","journal-title":"J Am Soc Echocardiogr"},{"key":"hoi260045r27","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-024-02576-2","article-title":"RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis.","author":"Schwarting","year":"2024","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"hoi260045r28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ehjci\/jeac136","article-title":"Right ventricular strain related to pulmonary artery pressure predicts clinical outcome in patients with pulmonary arterial hypertension.","volume":"24","author":"\u00dcnl\u00fc","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"hoi260045r29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.chest.2025.04.007","article-title":"Echocardiographic parameters and risk prediction in pulmonary arterial hypertension: insights from the Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics Network.","volume":"168","author":"Mukherjee","year":"2025","journal-title":"Chest"},{"issue":"19","key":"hoi260045r30","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.jacc.2023.03.392","article-title":"Multimodality imaging of right heart function: JACC Scientific Statement.","volume":"81","author":"Hahn","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"hoi260045r31","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi260045r32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","article-title":"Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy.","volume":"30","author":"Rettl","year":"2023","journal-title":"Amyloid"},{"issue":"5","key":"hoi260045r33","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/biomedicines13051211","article-title":"Incidence and predictors of right ventricular reverse remodeling in patients with transthyretin amyloid cardiomyopathy treated with tafamidis.","volume":"13","author":"Nita","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"hoi260045r34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10554-024-03293-7","article-title":"Recovery of right ventricular function in patients with transthyretin cardiac amyloidosis after one-year tafamidis administration.","volume":"41","author":"Nagai","year":"2025","journal-title":"Int J Cardiovasc Imaging"},{"issue":"9","key":"hoi260045r35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.039858","article-title":"Right ventricular-pulmonary artery uncoupling and strain in acute heart failure.","volume":"14","author":"Palazzuoli","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"hoi260045r16","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harrell","year":"2001"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2853333\/jamacardiology_jering_2026_oi_260045_1790870202.7842.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:00:57Z","timestamp":1791990057000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2853333"}},"subtitle":["Secondary Analysis of the HELIOS-B Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.3390","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}